<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149841">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02127788</url>
  </required_header>
  <id_info>
    <org_study_id>FR-MYC-NI-003</org_study_id>
    <nct_id>NCT02127788</nct_id>
  </id_info>
  <brief_title>Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology</brief_title>
  <acronym>OLYMPE</acronym>
  <official_title>National, Longitudinal, Multicentre and Prospective, Observational Study of the Use of Micafungin (Mycamine®) in Antifungal Prophylaxis of Invasive Fungal Infections in Medical Practice in Haematology and Onco-haematology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to describe the actual conditions of prescription
      of micafungin in antifungal prophylaxis in French haematological and onco-haematological
      units. The efficacy and the safety outcomes will be described.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Breakthrough incidence of Invasive Fungal Infection (IFI), defined according to the revised EORTC/MSG criteria, during prophylaxis use of micafungin</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC/MSG : European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Odds ratio and 95% CI for each identified risk factors</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of IFI, defined according to the revised EORTC/MSG criteria</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of patients treated with micafungin</measure>
    <time_frame>Day 0 (start of prophylaxis)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditions of use of micafungin</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>dose and administration pattern, temporary interruptions and treatment duration, oral treatment take-over</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>Up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of units</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>participating physicians (age, status, specialty), type of institution, location , type of unit, size of unit</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Antifungal Prophylaxis</condition>
  <condition>Haemopathy</condition>
  <arm_group>
    <arm_group_label>Micafungin</arm_group_label>
    <description>Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Micafungin</arm_group_label>
    <other_name>FK463</other_name>
    <other_name>Mycamine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized, adult patients with haemopathy or paediatric patients with haemopathy or
        solid tumor, under antifungal prophylaxis with micafungin.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.

          -  Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.

          -  Patient initiating antifungal prophylaxis with micafungin.

        Exclusion Criteria:

          -  Patient presenting documented fungal infection.

          -  Patient already included in a biomedical study impacting the care management of
             invasive fungal infection at the time of inclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical and Scientific Affairs Manager, Infectious Diseases</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma S.A.S.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical &amp; Clinical Operations Department</last_name>
    <phone>+31 (0)71 5455050</phone>
    <email>contact@nl.astellas.com</email>
  </overall_contact>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Micafungin</keyword>
  <keyword>Invasive Fungal Infection</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Haematology</keyword>
  <keyword>Observational study</keyword>
  <keyword>France</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
